Long-term safety of Tozorakimab in COPD patients with prior exacerbations

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

ROMEO is a Phase 3, multicenter, open-label extension that continues to dose tozorakimab in participants with COPD and prior exacerbations to assess long-term safety. It builds on prior trials by evaluating two dose regimens over an extended period. Eligibility requires completion of predecessor studies and affiliation with the French Social Security system, with informed consent as a must. The study design is open-label and focuses on safety and tolerability rather than efficacy endpoints. Sites are located in Aix-en-Provence, Brest, and Colmar, France, with AstraZeneca as the lead sponsor and several collaborators.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Participants previously randomized in predecessor studies.
2. Participants should be affiliated with the French Social Security system.
3. Participants who are willing to continue using contraceptive methods as agreed to for the predecessor studies.
4. Capable of giving signed informed consent.

Exclusion Criteria:

1. Clinically important pulmonary disease other than COPD.
2. Participant meeting criteria for IP discontinuation as judged by the Investigator or the Sponsor.
3. Current alcohol, drug or chemical abuse.
4. Treatment with systemic corticosteroids or other immunosuppressive medication within 2 weeks prior to Visit 1 of ROMEO.
5. Known history of:

   1. Severe allergic reaction to any monoclonal and polyclonal antibody.
   2. Allergy or reaction to any component of the IMP formulation.
6. Receipt of blood products or immunoglobulins within 30 days prior to visit 1 of ROMEO.
7. Receipt of live attenuated vaccines within 30 days prior to visit 1 of ROMEO.
8. Chronic use (or expected need for chronic use during the study) of immunosuppressive medications (including, but not limited to, systemic corticosteroids), marketed or investigational biologic, or another prohibited medication.
9. Chronic use of antibiotics if the duration of treatment is \< 3 months prior to Visit 1 of ROMEO (first IMP administration). Chronic macrolide or other antibiotic therapy is allowed provided the participant has been on a stable dose/regimen for ≥ 3 months prior to Visit 1 of ROMEO (first IMP administration) and has had at least one COPD exacerbation while on stable therapy.
10. Use of allergen immunotherapy within 3 months of Visit 1 of ROMEO (first IMP administration), except for stable maintenance dose allergen-specific immunotherapy started 4 weeks prior to V1.
11. Use of interferon gamma within 3 months of visit 1 of ROMEO (first IMP administration).
12. Participation in any interventional clinical trial or receipt of any investigational non-biologic product within 30 days or 5 half-lives prior to Visit 1 of ROMEO (first IMP administration), whichever is longer.
13. Involvement in the planning and/or conduct of the study (applies to both staff employed by the Sponsor and/or staff at the study site).
14. Participants who are not able to comply with the study requirements, procedures, and restrictions.

Where it's running

• Research Site
  Grenoble, France Recruiting
• Research Site
  Lyon, France Recruiting
• Research Site
  Marseille, France Recruiting
• Research Site
  Montpellier, France Recruiting
• Research Site
  Pessac, France Recruiting
• Research Site
  Aix-en-Provence, France Active not recruiting

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• One-time targeted lung denervation (dNerva) for people with COPD and lung hyperinflation

  This will see if a single dNerva targeted lung denervation procedure, added to usual COPD medications, improves breathing and lung function in people with COPD who have high residual lung volume and low emphysema.

  Recruiting at 10 sites Nuvaira, Inc. · Birmingham, Alabama and 9 other locations · NCT07051707

• Registry for COPD patients undergoing lung cancer screening

  This study looks at people with COPD who are getting screened for lung cancer to see how their condition affects their screening results and overall health.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT06974981

• Thermotherapy for persistent bacterial lung infections

  This study is testing if regular heat therapy can help people with chronic lung infections get rid of stubborn bacteria that don’t respond to regular antibiotics.

  Recruiting Chronic Obstructive Pulmonary Disease Trial Network, Denmark · Hellerup, Capital Region · NCT05351242

• AERO-007: a inhaled LABA+LAMA combination for COPD through a nebulizer

  This study tests whether a nebulized LABA+LAMA combination can improve lung function in adults with COPD.

  Recruiting Phase 2 AeroRx Therapeutics Inc. · London and 1 other locations · NCT07896252

• Flutter therapy added to chest physiotherapy after CABG in COPD patients

  This study tests whether adding Flutter therapy to standard chest physiotherapy helps post-CABG patients with mild-to-moderate COPD improve breathing more than chest physiotherapy alone.

  Recruiting Foundation University Islamabad · Rawalpindi · NCT07875049

• TPB-based cadence exercise and breathing training for COPD patients

  A TPB-based program tests whether breathing training, cadence-guided walking, or both can improve lung function, exercise capacity, and quality of life in adults with COPD.

  Recruiting Fu Jen Catholic University Hospital · New Taipei City, New Taipei City and 1 other locations · NCT07860008

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.